Esketamine for depression: all studies (page 13)

Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation.

Journal of Affective Disorders April 15, 2026 Jen-Ping Chen, Chih-Wei Hsu, Yi-Ting Chen et al.

Repetitive transcranial magnetic stimulation (rTMS) and esketamine are FDA-approved treatments for treatment-resistant depression (TRD), yet head-to-head comparative effectiveness data remain limited. Our study compared the effectiveness and safety profiles of rTMS versus esketamine in adults with TRD. This cohort study used target trial emulation with 1:1 propensity score matching on 50...

DOI: 10.1016/j.jad.2025.121132 Full text Esketamine Treatment-resistant depression Target trial emulation

Sustained effectiveness and safety of esketamine for major depressive disorder: a target trial simulation of real-world data.

Translational Psychiatry April 10, 2026 Ting-Hui Liu, Hong-Shiang Shen, Jheng-Yan Wu et al. 1 citation

This study aimed to evaluate the long-term effectiveness and safety of esketamine in adults with Major depressive disorder (MDD), focusing on suicide-related events, all-cause mortality, and major adverse cardiovascular events (MACEs). This target-trial simulation used the TriNetX Global Collaborative Network. Adults (≥ 18 years) with MDD who received either esketamine or a conventional...

DOI: 10.1038/s41398-026-04032-3 Full text Ketamine Major depressive disorder Humans Antidepressive agents +5

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Intranasal Esketamine for Rapid Symptom Relief in Treatment-resistant Depression.

Reviews on recent clinical trials April 7, 2026 Ritika Saun, Aakriti Garg, Mohd Ashif Khan

Most of the Major Depressive Disorder (MDD) patients experience Treatment-Resistant Depression (TRD), wherein standard pharmaceutical and psychological interventions fail to provide adequate symptom relief. This systematic review and meta-analysis investigated the efficacy and safety of intranasal esketamine for rapid symptom relief in adults with TRD. The search strategy adhered to PRISMA...

DOI: 10.2174/0115748871407261251215071206 Full text Mdd Esketamine Major depressive disorder Severe depression +2

Esketamine prevents postpartum depression after cesarean section: a Meta-analysis

Yixue xinzhi zazhi April 2, 2026 Yao Wenzhuang, Zhang Hanyun, Liu Suman et al.

Objective To systematically evaluate the efficacy and safety of Esketamine on postpartum depression (PPD) in cesarean section women.Methods Databases including PubMed, Embase, Web of Science, The Cochrane Library, CBM, CNKI, WanFang and VIP were searched from inception to March 2025 for RCTs investigating the impact of Esketamine on PPD in cesarean section parturients. RevMan 5.4 and Stata 18.0...

DOI: 10.12173/j.issn.1004-5511.202505094 Full text Esketamine Cesarean section Postpartum depression Patient-controlled intravenous analgesia +1

Metabolomic Profiling of Extracellular Vesicles Reveals Distinct Metabolic Dysregulation and Treatment-Specific Signatures in Depression.

Biomolecules April 2, 2026 Nikola Balic, Gordana Nedic Erjavec, Marcela Konjevod et al.

Major depressive disorder (MDD) is associated with complex metabolic alterations. In this study, we applied a multiplatform metabolomics approach (GC-MS and LC-MS) to characterize the plasma extracellular vesicle (EV) metabolome in healthy controls (N = 50), responsive MDD patients (N = 60), and patients with treatment-resistant depression (TRD; N = 65). Longitudinal analyses were performed...

DOI: 10.3390/biom16040533 Full text Mdd Esketamine Trd Bright-light therapy +4

Emerging Clinical Applications of Ketamine and Esketamine Across Psychiatric Disorders.

FOCUS: The Journal of Lifelong Learning in Psychiatry April 1, 2026 Rachel Fremont, Marcella Corwin, Greta Kandel et al.

Over the past 25 years, the field of psychiatry has seen a rapid expansion of ketamine treatment services offered for the off-label management of depression, anxiety, and other psychiatric disorders as well as the U.S. Food and Drug Administration's approval of intranasal esketamine, the S-enantiomer of ketamine, for treatment-resistant depression and suicidal depression. In this review, the...

DOI: 10.1176/appi.focus.20250046 Full text Depression Esketamine Academic psychiatry Antidepressants

Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study.

FOCUS: The Journal of Lifelong Learning in Psychiatry April 1, 2026 Naim Zaki, Li Nancy Chen, Rosanne Lane et al.

Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to patients with major depressive disorder who are not treatment-resistant, underscoring the need for treatment choices with sustained efficacy and long-term tolerability. Adults with TRD who participated in ≥1 of 6 phase 3...

DOI: 10.1176/appi.focus.26024111 Full text

Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study.

PLoS Medicine April 1, 2026 Yifan Li, Vivien Kin Yi Chan, Mark Jit et al.

Treatment-resistant depression (TRD), defined as failure to respond to at least two adequately administered antidepressant (AD) regimens, imposes major clinical and economic burdens. Esketamine nasal spray offers rapid antidepressant clinical effects, yet previous evaluations compared it only with unrealistic comparators such as AD monotherapy. This study assessed the cost-effectiveness of...

DOI: 10.1371/journal.pmed.1005047 Full text

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series.

European Journal of Psychotraumatology April 1, 2026 Maud Rothärmel, Lila Mekaoui, François Kazour et al. 1 citation

Background: Posttraumatic stress disorder (PTSD) is a severe and frequent affection that is highly comorbid to major depressive disorder. Comorbid PTSD and depression increase the risk of treatment-resistant depression (TRD), with a high risk of functional impairment and suicide. Esketamine nasal spray is a recent validated treatment for TRD, but its efficacy on comorbid TRD-PTSD remains...

DOI: 10.1080/20008066.2025.2609425 Full text Treatment-resistant depression Esketamine nasal spray Post-traumatic stress disorder Real-life data +2

Management of Treatment-Resistant Depression: An Updated Narrative Review of Current and Emerging Treatments.

Cureus April 1, 2026 Juan Pablo Berlin Viniegra

Treatment-resistant depression (TRD) remains a major clinical challenge in psychiatric practice and affects a substantial proportion of patients with major depressive disorder (MDD). It is commonly defined as failure to achieve remission after at least two adequately conducted antidepressant trials. TRD is associated with persistent functional impairment, increased morbidity, reduced quality of...

DOI: 10.7759/cureus.107343 Full text Esketamine Major depressive disorder Augmentation strategies Deep brain stimulation +4

Research